SCHEDULE: Caligan Partners Discloses 6.3% Stake in Avalo Therapeutics
Beneficial Ownership Disclosure
Caligan Partners LP and David Johnson have reported a passive 6.3% ownership stake in Avalo Therapeutics, Inc., holding 833,333 shares of common stock.
Summary
- Caligan Partners LP and David Johnson collectively beneficially own 833,333 shares of Avalo Therapeutics, Inc. Common Stock.
- This ownership represents 6.3% of the company's outstanding Common Stock.
- The percentage is calculated based on 13,152,356 shares outstanding as of August 6, 2025, as reported in Avalo Therapeutics' Form 10-Q for the quarter ended June 30, 2025.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Caligan Partners LP is a Delaware limited partnership, and David Johnson is a United States citizen, serving as Managing Partner of Caligan.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, providing no direct positive or negative operational or financial news for the company. The sentiment is neutral as it simply reports a stake.
Positives
- A significant institutional investor, Caligan Partners LP, has disclosed a substantial stake, potentially signaling confidence in Avalo Therapeutics' future prospects.
- The investment is stated to be for passive purposes, indicating no immediate intent to influence or change control of the company.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded biotechnology company. Such disclosures are common and can sometimes indicate increased investor interest in the sector or specific company.
Stakeholder Impact
- Shareholders may view the disclosure of a significant stake by an institutional investor as a positive signal, potentially increasing confidence in the company's stock.
- The company's management and board may note the increased ownership by a specific entity, though the filing indicates a passive investment intent.
Key Dates
| Date | Description |
|---|---|
| 2025-08-06 | Date as of which 13,152,356 shares of Common Stock were reported outstanding in the Company's Form 10-Q. |
| 2025-09-30 | Date of event which requires the filing of this statement. |
| 2025-11-14 | Date the Schedule 13G statement was signed and filed. |
Keywords
Avalo Therapeutics, Caligan Partners, David Johnson, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.